151751-Najiba-Chargi

22 CHAPTER 1 REFERENCES 1. Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer . 2018;18(5):269-282. doi:10.1038/nrc.2018.11 2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer sta - tistics 2018: GLOBOCAN estimates of in - cidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin . 2018;68(6):394-424. doi:10.3322/caac.21492 3. NKR Cijfers - IKNL. https://iknl.nl/nkr-cijfers Accessed December 30, 2020. 4. Reproduced with permission from Longo DL, Chow LQM. Head and Neck Cancer. New Engl J Med Downloaded from nejm.org Univ Libr Utr . 2020;382:60-72. doi:10.1056/ NEJMra1715715. Copyright Medical Society. 5. Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer in - cidence, mortality, years of life lost, years lived with disability, and disability-adjust- ed life-years for 32 cancer groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study Global Burden of Disease Cancer Collaboration. JAMA Oncol . 2017;3(4):524-548. doi:10.1001/jamaon - col.2016.5688 6. Rettig EM, D’Souza G. Epidemiology of Head and Neck Cancer. Surg Oncol Clin N Am . 2015;24(3):379-396. doi:10.1016/j. soc.2015.03.001 7. Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer in - cidence, mortality, years of life lost, years lived with disability, and disability-adjust- ed life-years for 32 cancer groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study Global Burden of Disease Cancer Collaboration. JAMA Oncol . 2017;3(4):524-548. doi:10.1001/jamaon - col.2016.5688 8. Ang KK, Harris J, Wheeler R, et al. Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. N Engl J Med . 2010;363(1):24-35. doi:10.1056/ nejmoa0912217 9. Yip C, Goh V, Davies A, et al. Assessment of sarcopenia and changes in body com- position after neoadjuvant chemother - apy and associations with clinical out- comes in oesophageal cancer. Eur Radiol . 2014;24(5):998-1005. doi:10.1007/s00330- 014-3110-4 10. Marur S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: A virus-related cancer epidemic. Lancet Oncol . 2010;11(8):781-789. doi:10.1016/ S1470-2045(10)70017-6 11. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a popu- lation-based to a more “personalized” ap- proach to cancer staging. CA Cancer J Clin . 2017;67(2):93-99. doi:10.3322/caac.21388 12. Pignon JP, Maître A le, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Ra- diother Oncol . 2009;92(1):4-14. doi:10.1016/j. radonc.2009.04.014 13. Forastiere AA, Goepfert H, Maor M, et al. Concurrent Chemotherapy and Radio- therapy for Organ Preservation in Ad - vanced Laryngeal Cancer. N Engl J Med . 2003;349(22):2091-2098. doi:10.1056/ nejmoa031317 14. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squa - mous-Cell Carcinoma of the Head and Neck. N Engl J Med . 2004;350(19):1937-1944. doi:10.1056/nejmoa032646